Asymchem Laboratories (Tianjin) Co., Ltd. (HKG:6821)
97.55
+1.25 (1.30%)
Sep 10, 2025, 1:44 PM HKT
HKG:6821 Revenue
Asymchem Laboratories (Tianjin) had revenue of 1.65B CNY in the quarter ending June 30, 2025, with 26.94% growth. This brings the company's revenue in the last twelve months to 6.30B, up 6.69% year-over-year. In the year 2024, Asymchem Laboratories (Tianjin) had annual revenue of 5.80B, down -25.82%.
Revenue (ttm)
6.30B CNY
Revenue Growth
+6.69%
P/S Ratio
5.98
Revenue / Employee
656.13K CNY
Employees
9,595
Market Cap
41.25B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 5.80B | -2.02B | -25.82% |
Dec 31, 2023 | 7.83B | -2.40B | -23.51% |
Dec 31, 2022 | 10.23B | 5.60B | 120.85% |
Dec 31, 2021 | 4.63B | 1.50B | 47.67% |
Dec 31, 2020 | 3.14B | 676.74M | 27.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines AG | 35.81B |
Hansoh Pharmaceutical Group Company | 14.45B |
JD Health International | 71.34B |
Innovent Biologics | 12.52B |
Sino Biopharmaceutical | 33.49B |
WuXi Biologics | 21.98B |
Akeso | 2.75B |
CSPC Pharmaceutical Group | 28.49B |